Lithuania

 

Affidea bought by Groupe Bruxelles Lambert

Groupe Bruxelles Lambert (“GBL”) has signed definitive agreements to acquire a majority stake in European imaging and cancer treatment provider Affidea from B-FLEXION, the private investment firm of the Switzerland-based billionaire Bertarelli family. GBL will invest up to €1bn of equity for the transaction which is its first substantive healthcare investment.
April 19, 2022

Will record results for Synlab precipitate Cinven sale?

Almost a year after its IPO, lab giant Synlab has posted strong FY21 results bolstered by Covid, but not, it says, dependant on it. Management say extra cash will be used as a springboard for growth. Could it also lead to private equity majority shareholder Cinven selling its remaining interest?
March 17, 2022

Affidea sale – potential price and buyers

European imaging and cancer treatment provider Affidea is for sale according to multiple sources. HBI chats to an operator source to find about more about the sale and to speculate on price and purchasers.
December 22, 2021

How Affidea is driving 10% MRI scan growth

European imaging provider Affidea sees 10% volume growth on MRI scans where it has deployed a programme to track how and when machines are used with proprietary software. Senior VP regional COO Zisis Sotiriou talks to HBI about how it has optimised clinical protocols, identified efficiency savings and gained an extra €2m revenue a year.
September 16, 2021

Interview: Maris Revalds, Chairman, Health Center 4

Anyone paying attention to the Baltic healthcare market - and at just six million people you'd be forgiven for not - will have noticed an aggressive consolidation of the sector by pharmacy chain & wholesaler, Repharm; something rarely seen elsewhere. Health Center 4 (Veselības centrs 4) is the second-largest to it in Latvia and chairman Revalds speaks on his competitor's moves while also giving us an overview of his business and the local market.
August 10, 2021

Interview: Arjan Toor, CEO, Cigna Europe

Cigna now describes itself as “a global health service company” rather than an insurer and has reorganised its European operations. Toor has recently been promoted to CEO Europe. He says that the insurer, which has 15% (US$840m) of its revenue in Europe, doesn't want to verticalise through owning primary care providers but wants instead to provide an end-to-end user experience.
July 21, 2020
Newer posts
Older posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us